Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions

Journal of Investigative Dermatology

Volumn 111, Issue 3, 1998, Pages 497-502

  Geertsen, Ralf Christian ^a   Hofbauer, Günther Franz L ^a   Yue, Feng Yun ^a   Manolio, Silvana ^a   Burg, Günter ^a   Dummer, Reinhard ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

HLA I; HLA II; ICAM 1

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MELANOMA ANTIGEN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOSS; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL;

EID: 0031660839     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00305.x     Document Type: Article

References (44)

1. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG: Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 269:20126-20133, 1994
2. Altschul S, Gish W, Miller W, Myers E, Lipman D: Basic local alignment search tool. J Mol Biol 215:403-410, 1990
3. Bakker AB, de Schreurs MWBA, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994
4. Becker JC, Brocker EB: Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 139:205-214, 1995
5. Becker JC, Termeer C, Schmidt RE, Brocker EB: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151:7224-7232, 1993
6. Brichard VG, Herman J, Van Pel A, et al: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26:224-230, 1996
7. van der Bruggen P, Bastin J, Gajewski T, et al: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043, 1994
8. Carrel S, Dore JF, Ruiter DJ, et al: The EORTC Melanoma Group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer 48:836-847, 1991
9. Carrel S, Salvi S, Hartmann F, Rimoldi D: Recognition of HLA-A1 by murine monoclonal antibodies. Tissue Antigens 43:110-115, 1994
10. Cordell JL, Falini B, Erber WN, et al: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-229, 1984
11. Cromme FV, van Bommel PF, Walboomers JM, et al: Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69:1176-1181, 1994
12. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S: Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 87:284-292, 1991
13. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019-1025, 1988
14. Dupont B (ed.): Histocompatibility testing. In: Immunobiology of HLA, Vol. 1, New York: Springer Verlag, 1987
15. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494, 1995
16. Garrido F, Ruiz-Caballo F, Cabrera T, Pérez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA-class I phenotypes in human tumors. Immunol Today 18:89-95, 1997
17. Griffioen M, Peltenburg LT, van Oorschot DA, Schrier PI: C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiology 193:238-247, 1995
18. Herman J, van der Bruggen P, Luescher IF, et al: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 43:377-383, 1996
19. Hoon DSB, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109-2116, 1995
20. Jager E, Bernhard H, Romero P, et al: Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162-169, 1996
21. Jager E, Ringhoffer M, Altmannsberger M, et al: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142-147, 1997
22. Kageshita T, Wang Z, Calorini L, et al: Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 53:3349-3354, 1993a
23. Kageshita T, Yoshii A, Kimura T, et al: Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 53:4927-4932, 1993b
24. Kawakami Y, Eliyahu S, Sakaguchi K, et al: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352, 1994
25. Keating PJ, Cromme FV, Duggan-Keen M, et al: Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405-411, 1995
26. Kirkwood JM, Strawderman MH, Emstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 [see comments]. J Clin Oncol 14:7-17, 1996
27. Lehmann F, Marchand M, Hainaut P, et al: Differences in the antigens recognized by cytolyric T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340-347, 1995
28. Luboldt HJ, Kubens BS, Rubben H, Grosse-Wilde H: Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56:826-830, 1996
29. Luescher IF, Romero P, Kuznetsov D, Rimoldi D, Coulie P, Cerottini JC, Jongeneel CV: HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. J Biol Chem 271:12463-12471, 1996
30. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT: New treatment options for patients with melanoma: review of melanoma-derived T cell epitope-based peptide vaccines. Melanoma Res 6:11-24, 1996
31. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S: Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma: cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 88:282-289, 1991
32. Marincola FM, Shamamian P, Alexander RB, et al: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153:1225-1237, 1994
33. Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 86:6719-6723, 1989
34. Nestle F, Alijagic S, Gilliet M, et al: D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 4:328-332, 1998
35. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100-108, 1996
36. Rivoltini L, Barracchini KC, Viggiano V, et al: Quantitative correlation between HLA class 1 allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55:3149-3157, 1995
37. Rock KL, Clark K: Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156:3721-3726, 1996
38. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S: MHC antigens in human melanomas. Semin Cancer Biol 2:35-45, 1991
39. Schadendorf D, Fichtner I, Makki A, Alijagic S, Kupper M, Mrowietz U, Henz BM: Metastatic potential of human melanoma cells in nude mice - characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer 74:194-199, 1996
40. Straten PT, Kirkin AF, Seremet T, Zeuthen J: Expression Of Transporter Associated With Antigen Processing 1 and 2 (Tap1/2) In Malignant Melanoma Cell Lines. Int J Cancer 70:582-586, 1997
41. Topalian SL, Gonzales MI, Parkhurst M, et al: Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965-1971, 1996
42. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764, 1994
43. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G: Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71:630-637, 1997
44. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA: Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 53:5-8, 1993